Evidence Hub

Possibilities of a preparation omega-3 polyunsaturated fatty acids in the treatment of patients with ventricular arrhythmias and myocardial infarction

Gogolashvili NG, Litvinenko MV, Pochikaeva TN, Vavitova ES, Polikarpov LS, Novgorodtseva NIa

Kardiologiia, 2011

56 participants

Abstract

The aim was to study the effectiveness of prescription medication containing 90% omega-3 polyunsaturated fatty acids for 6 months on ventricular arrhythmias in patients with myocardial infarction less than a year ago. The study involved 56 patients with ventricular extrasystoles, from 500 to 1000 per day. Divided into two groups of patients we divided into I group - 30 people - received in addition to standard drug therapy of omega-3 PUFA 1 g daily, for 6 months; II group - 26 men were given only previously assigned therapies. The average age of patients in group I - 60,7+/-8,6, II group - 61+/-9,7 years (p> 0,05). ECG monitoring was performed at 3 and 6 months. Administration of highly concentration preparation of omega-3 PUFAs for 3 months reduced number of PVCs per day, frequencies of grades 2, 3, 4A, 4B, and high grade PVCs (grades 3 - 5) as a whole. These effects persisted after 6 months of treatment.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 56 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free